NEUWAY Pharma and WACKER Launch Research Project to Develop RNA-Based Actives for the Treatment of Central Nervous System Diseases
Munich and Bonn, October 12, 2022 – Bonn-based biotech company NEUWAY Pharma and Munich-based chemical company WACKER have launched a research project to identify and manufacture RNA-based actives for the treatment of diseases of the central nervous system (CNS). They will make use of NEUWAY’s protein-based drug delivery technology EnPC®. EnPC® allows for targeted drug delivery via the blood-brain barrier into the CNS.För mer information se bifogad pressrelease.